Technology Appraisal (Committee B) meeting minutes

**Minutes:** Confirmed

**Date and Time:** Thursday 12 November 2020

**Location:** via Zoom

# Present:

• Professor Amanda Adler (Chair) Present for all notes

• Dr Sanjeev Patel (Vice-Chair) Present for all notes

• Dr Carlo Berti Present for notes 9 to 18

• Dr Laura Bojke Present for all notes

• Mr Mark Chapman Present for all notes

• Dr Mark Glover Present for all notes

• Dr Megan John Present for all notes

• Professor Sanjay Kinra Present for all notes

• Dr Nicholas Latimer Present for all notes

• Dr Veline L'Esperance Present for all notes

• Dr Rhiannon Owen Present for all notes

• Ms Anna Pracz Present for all notes

• Dr Stephen Smith Present for all notes

• Professor Nicky Welton Present for all notes

• Mr Nigel Westwood Present for all notes

• Mr Peter Wheatley Price Present for notes 1-8 & 14-18

• Professor Sarah Wild Present for all notes

• Dr Ed Wilson Present for all notes

• Mr Tony Wootton Present for all notes

# In attendance:

* Henry Edwards, Associate Director, NICE, Present for notes 25 to 33.
* Nicole Elliott, Associate Director, NICE, Present for notes 1 to 13
* Joanne Ekeledo, Project Manager, NICE, Present for notes 1 to 13
* Thomas Feist, Project Manager, NICE, Present for notes 25 to 33
* Mira Patel, Administrator, NICE, Present for note 9 to 18
* Sophie McHugh, Administrator, NICE, Present for all notes
* Mandy Brereton, Assistant Project Manager, Present for notes 9 to 18
* Emma Douch, Technical Analyst, NICE, Present for notes 1 to 8
* Lorna Dunning, Technical Adviser, NICE, Present for notes 1 to 8
* Hannah Nicholas, Technical Analyst, NICE, Present for notes 9 to 13
* Carl Prescott, Technical Adviser, NICE, Present for notes 9 to 13
* Caroline Bregman, Technical Analyst, NICE, Present for notes 14 to 18
* Eleanor Donegan, Technical Adviser, NICE, Present for notes 14 to 18
* Robert Wolff, Kleijnen Systematic Reviews, Evidence Review Group, Present for notes 1 to 13
* Bram Ramaeker, Kleijnen Systematic Reviews, Evidence Review Group, Present for notes 1 to 13
* Emma Knowles, PenTAG, Evidence Review Group, Present for notes 14 to 21
* G.J-Melendez-Torres, PenTAG, Evidence Review Group, Present for notes 14 to 21
* Jo Lord, Southampton Health Technology Assessment Group, Evidence Review Group, Present for notes 26 to 30
* Jo Picot, Southampton Health Technology Assessment Group, Evidence Review Group, Present for notes 26 to 30
* Janine Beezer, Clinical Expert, Advanced Clinic Pharmacist, Present for notes 1 to 13
* Dr Klaus Witte, Clinical Expert, Associate Professor and Consultant Cardiologist, Present for notes 1 to 13
* Mr Nick Hartshorne-Evans, Patient Expert, CEO, Present for notes 1 to 13
* Mrs Sarah Worsnop, Patient Expert, Patient Educator, Present for notes 1 to 13
* Prof Peter Clark, Cancer drugs Fund Clinical Lead, Present for all notes
* Karthik Ramasamy, Clinical Expert, Consultant Haematologist, Oxford University Hospital, Present for notes 14 to 20
* Mathew Jenner, Clinical Expert, Consultant Haematologist University Hospital Southampton NHS Foundation Trust, Present for notes 14 to 20
* Shelagh McKinley, Clinical Expert, Head of Patient Advocacy, Myeloma UK, Present for notes 14 to 20
* Stephen Billcliffe, Clinical Expert, Nominated by Myeloma UK, Present for notes 14 to 20

# Non-public attendees:

* Dawn Abbott, Reception and Office Assistant & NICE Observer, Present for all notes
* Sola Akinbolade, Evidence Synthesis/Horizon Scanning Specialist - NIHRIO & NICE Observer, Present for notes 1 to 8
* Helen Barnett, Senior Medical Editor & NICE Observer, Present for all notes
* Caroline Bregman, Technical analyst & NICE Observer, Present for notes 26 to 30
* Emilene Coventry, Senior Medical Editor & NICE Observer, Present for notes 1 to 8
* Caroline Farmer, Research Fellow & NICE Observer, Present for notes 14 to 21
* Hayley Garnett, Senior Medical Editor & NICE Observer, Present for notes 1 to 22
* Cara Gibbons, Assistant Health Technology Assessment Analyst & NICE Observer, Present for notes 1 to 8
* Joanna Gray, Specialty Registrar (ST3) in Clinical Pharmacology and Therapeutics and General Internal Medicine - Addenbrookes & NICE Observer, Present for notes 1 to 9
* Ella Livingstone, TA (PASLU) & NICE Observer, Present for all notes
* Heidi Livingstone, Senior Public Involvement adviser, NICE, Present for notes 1 to 8
* Emily Leckenby, Technical Analyst & NICE Observer, Present for notes 1 to 8
* Laura Marsden, Public Involvement adviser, NICE, Present for notes 1 to 8
* Edgar Masanga, RIA lead & NICE Observer, Present for all notes
* Sandra Robinson, Corporate Office Coordinator, NICE, Present for all notes
* Rebecca Thomas, Assistant Health Technology Assessment Analyst & NICE Observer, Present for notes 25 to 29
* Sharlene Ting, Technical Analyst & NICE Observer, Present for notes 1 to 8

# Notes

## Any other business

1. None.

## Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on Wednesday 14 October 2020.

## Appraisal of Dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Astrazeneca UK Ltd.
2. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests.

* 1. Dr Klaus Witte declared the following:

Direct non-financial interest; he participated in Educational activities, a primary school education video and classroom teaching in October/ November 2019. The activities were paid for by Bayer.

Direct financial interest - out of hours generic primary care discussions on the optimal management of diabetes (not heart failure) for which he received an honorarium in September 2019; November 2019, January 2020 and February 2020.

Direct financial interest – he participated in an advisory board in January funded by AstraZeneca, to discuss how dapagliflozin would fit into the existing pathway for the management of heart failure. Direct financial interest; he also attended numerous other non-promotional educational meetings:

* + September 2019, European Society of Cardiology invited to speak – Sacubatril/valsartan funded by Novartis
	+ September 2019, European Society of Cardiology invited to speak - Rivaroxaban funded by Bayer
	+ March 2020, diabetes management funded by Pfizer/BMS
		1. It was agreed that this declaration would not prevent Dr Klaus Witte from participating in this section of the meeting.
1. Mr Nick Hartshorne-Evans declared a direct non-financial interest as he was a speaker at the ‘hackathon’ the monies received went to the Pumping Marvellous charity and not Nick himself.
	* 1. It was agreed that this declaration would prevent Mr Nick Hartshorne-Evans participating in this section of the meeting.
2. No further conflicts of interest were declared for this appraisal.
3. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
4. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. Details of the result of this discussion will be given in the ACD or FAD, which will be published in due course.
4. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of lenalidomide for the maintenance treatment of multiple myeloma after autologous stem cell transplantation [ID475]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Celgene UK Ltd.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests
3. Shelagh McKinlaydeclared an indirect financial interest as Myeloma UK receives funding, mainly project specific, from Celgene, Amgen and Janssen

It was agreed that this declaration would not prevent them from participating in this section of the meeting

1. Dr Karthik Ramasamy declared a direct financial interest as he has received research grants, honoraria, speaker fees from Celgene.

It was agreed that this declaration would not prevent them from participating in this section of the meeting.

1. Dr Matthew Jenner declared a direct financial interest as he has received Honoraria from Celgene BMS for advisory board regarding CAR-T cell therapy in myeloma. November 2019 and November 2020.

It was agreed that this declaration would prevent them from participating in this section of the meeting.

1. Peter Wheatley Price was conflicted for this topic as Takeda manufacture Ninlaro (ixazomib citrate) which is on patent and promoted. It has a licence "NINLARO in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy". Ninlaro is funded via a CDF agreement.
2. No further conflicts of interest were declared for this appraisal.
3. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
4. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2a – Closed session (company representatives, clinical and patient experts and members of the public were asked to leave the meeting)

1. The ERG remained for part 2a
2. The committee discussed confidential information submitted as part of this appraisal.

### Part 2b – Closed session (ERG/AG representatives were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of Dupilumab for treating severe asthma [ID1213]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Sanofi.
2. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests.
3. No conflicts of interest were declared for this appraisal.
4. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
5. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. Details of the result of this discussion will be given in the ACD or FAD, which will be published in due course during the week commencing [w/c date for release of FAD] after the publication of all decisions taken at this Committee meeting.’
3. The committee asked the NICE technical team to prepare Final Appraisal Determination (FAD) in line with their decisions.